Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults.

Hendricks KA, Wright ME, Shadomy SV, Bradley JS, Morrow MG, Pavia AT, Rubinstein E, Holty JE, Messonnier NE, Smith TL, Pesik N, Treadwell TA, Bower WA; Workgroup on Anthrax Clinical Guidelines.

Emerg Infect Dis. 2014 Feb;20(2). doi: 10.3201/eid2002.130687.

2.

Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women.

Meaney-Delman D, Zotti ME, Creanga AA, Misegades LK, Wako E, Treadwell TA, Messonnier NE, Jamieson DJ; Workgroup on Anthrax in Pregnant and Postpartum Women.

Emerg Infect Dis. 2014 Feb;20(2). doi: 10.3201/eid2002.130611.

3.

Clinical Framework and Medical Countermeasure Use During an Anthrax Mass-Casualty Incident.

Bower WA, Hendricks K, Pillai S, Guarnizo J, Meaney-Delman D; Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2015 Dec 4;64(4):1-22. doi: 10.15585/mmwr.rr6404a1.

PMID:
26632963
4.

An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program.

Martin SW, Tierney BC, Aranas A, Rosenstein NE, Franzke LH, Apicella L, Marano N, McNeil MM.

Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):393-401.

PMID:
15717323
5.

Pediatric anthrax clinical management: executive summary.

Bradley JS, Peacock G, Krug SE, Bower WA, Cohn AC, Meaney-Delman D, Pavia AT; AAP Committee on Infectious Diseases and Disaster Preparedness Advisory Council.

Pediatrics. 2014 May;133(5):940-2. doi: 10.1542/peds.2014-0564. No abstract available.

6.
7.

Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax.

Tierney BC, Martin SW, Franzke LH, Marano N, Reissman DB, Louchart RD, Goff JA, Rosenstein NE, Sever JL, McNeil MM; Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program.

Clin Infect Dis. 2003 Oct 1;37(7):905-11. Epub 2003 Sep 12.

PMID:
13130401
8.

Learning from the 2001 anthrax attacks: immunological characteristics.

Hadler JL.

J Infect Dis. 2007 Jan 15;195(2):163-4. Epub 2006 Dec 6. No abstract available.

PMID:
17191158
9.

Antitoxin Treatment of Inhalation Anthrax: A Systematic Review.

Huang E, Pillai SK, Bower WA, Hendricks KA, Guarnizo JT, Hoyle JD, Gorman SE, Boyer AE, Quinn CP, Meaney-Delman D.

Health Secur. 2015 Nov-Dec;13(6):365-77. doi: 10.1089/hs.2015.0032. Review.

10.
11.

The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.

Doolan DL, Freilich DA, Brice GT, Burgess TH, Berzins MP, Bull RL, Graber NL, Dabbs JL, Shatney LL, Blazes DL, Bebris LM, Malone MF, Eisold JF, Mateczun AJ, Martin GJ.

J Infect Dis. 2007 Jan 15;195(2):174-84. Epub 2006 Dec 6.

PMID:
17191162
12.

Anthrax. From bioweapons backwater to main attraction.

Bohannon J.

Science. 2003 Apr 18;300(5618):414-5. No abstract available.

PMID:
12702854
13.

BioThrax and Anthrasil for anthrax.

[No authors listed]

Med Lett Drugs Ther. 2016 May 9;58(1494):62. No abstract available.

PMID:
27148924
14.

Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax.

Yamamoto BJ, Shadiack AM, Carpenter S, Sanford D, Henning LN, Gonzales N, O'Connor E, Casey LS, Serbina NV.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5796-805. doi: 10.1128/AAC.01102-16. Print 2016 Oct.

15.

Pediatric anthrax clinical management.

Bradley JS, Peacock G, Krug SE, Bower WA, Cohn AC, Meaney-Delman D, Pavia AT; AAP Committee on Infectious Diseases and Disaster Preparedness Advisory Council.

Pediatrics. 2014 May;133(5):e1411-36. doi: 10.1542/peds.2014-0563.

16.

Conference report on public health and clinical guidelines for anthrax.

Stern EJ, Uhde KB, Shadomy SV, Messonnier N.

Emerg Infect Dis. 2008 Apr;14(4). pii: 07-0969. doi: 10.3201/eid1404.070969.

17.

Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2002 Nov 15;51(45):1024-6.

18.

Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax.

Mytle N, Hopkins RJ, Malkevich NV, Basu S, Meister GT, Sanford DC, Comer JE, Van Zandt KE, Al-Ibrahim M, Kramer WG, Howard C, Daczkowski N, Chakrabarti AC, Ionin B, Nabors GS, Skiadopoulos MH.

Antimicrob Agents Chemother. 2013 Nov;57(11):5684-92. doi: 10.1128/AAC.00458-13. Epub 2013 Aug 26.

19.

Anthrax: safe treatment for children.

Benavides S, Nahata MC.

Ann Pharmacother. 2002 Feb;36(2):334-7. Review.

PMID:
11847958
20.

Raxibacumab.

Mazumdar S.

MAbs. 2009 Nov-Dec;1(6):531-8. Epub 2009 Nov 29. Review.

Supplemental Content

Support Center